High Depth Proteomics of Synovial Fluid Reveals Osteoarthritis Biomarkers

Importance of the topic

Osteoarthritis (OA) is the most prevalent form of arthritis and currently lacks disease-modifying therapies. Synovial fluid (SF) reflects joint biology and is therefore a promising liquid biopsy for discovery of diagnostic and prognostic biomarkers as well as candidate therapeutic targets. However, SF proteomics is technically challenging because of extreme protein concentration dynamic range and low available volumes. Methods that increase proteome depth, reproducibility and throughput from small SF volumes can accelerate biomarker discovery and downstream clinical translation.

Objectives and study overview

This study aimed to maximize proteome coverage of human synovial fluid and to identify proteins and pathways associated with osteoarthritis. The authors combined the PreOmics Enrich-iST sample preparation workflow with Bruker timsTOF Ultra operated in AIP (advanced ion processing) dia-PASEF mode to profile SF from knee joints of OA patients and healthy controls. Key goals were to achieve deep, label-free proteome coverage without peptide fractionation or depletion, demonstrate technical reproducibility, and highlight candidate OA-associated proteins and pathways.

Methods

Sample cohort and input

• Synovial fluid: 10 µL per injection from knee joints; cohort comprised healthy controls (n=4) and OA patients (n=4).

Sample preparation and LC-MS workflow

• Sample cleanup and peptide enrichment: PreOmics Enrich-iST kit.
• LC system and column: EVOSEP One with a 30 SPD method; PepSep analytical column (15 cm × 150 µm, 1.5 µm particles).
• Mass spectrometry: Bruker timsTOF Ultra in AIP mode with CaptiveSpray Ultra source; dia-PASEF acquisition (ion mobility window IM 0.75–1.3 V·s/cm², m/z 100–1,700).
• Data processing: Spectronaut 20 (directDIA+ mode) searched against the reviewed human UniProtKB database; downstream statistics performed in R and Python.

Instrumentation used

• PreOmics Enrich-iST sample preparation kit.
• EVOSEP One LC system.
• PepSep 15 cm × 150 µm column (1.5 µm).
• Bruker timsTOF Ultra mass spectrometer with AIP and CaptiveSpray Ultra ion source.
• Data analysis: Spectronaut 20 (directDIA+), R and Python for statistics.

Main results and discussion

Proteome depth and reproducibility

• The workflow identified approximately 4,800 protein groups and ~45,000 peptides per synovial fluid sample without offline fractionation or depletion—reported by the authors as a record depth for unfractionated SF.
• Technical reproducibility was high, with median coefficients of variation (CVs) ≤10% at both peptide and protein levels.

Biological separation and differential expression

• Multivariate analysis (principal component analysis) clearly separated OA patient samples from healthy controls, indicating distinct SF proteomic signatures.
• Statistical testing revealed numerous proteins significantly up- or downregulated in OA; matrix metalloproteinases (MMPs) were among the most notable changes, consistent with cartilage matrix degradation in OA.
• Gene Ontology and pathway enrichment analysis highlighted alterations in extracellular matrix remodeling, inflammatory signaling, cytokine production, and immune response pathways—processes mechanistically linked to OA pathophysiology.

Interpretation and limitations

• The combination of Enrich-iST and timsTOF Ultra AIP enables deep proteome coverage from very small SF volumes, making high-content discovery feasible from routine clinical samples.
• Study limitations include a small clinical cohort (n=8 total), which limits statistical power and generalizability; findings require validation in larger, independent cohorts and orthogonal assays (e.g., targeted MS or immunoassays).
• No fractionation/depletion simplifies workflow and preserves low-abundance proteins but may still miss the very lowest-abundance biomarkers; potential biases introduced by enrichment chemistry should be evaluated.

Benefits and practical applications

• The protocol achieves exceptional depth with a low sample volume (10 µL), enabling biomarker discovery from scarce clinical materials.
• High reproducibility (median CV ≤10%) supports robust comparative studies and prioritization of biomarker candidates.
• Unbiased discovery of MMPs and immune/inflammatory pathways provides mechanistic insights and nominates targets for therapeutic intervention or development of targeted assays (MRM/PRM, immunoassays).
• The streamlined, unfractionated workflow reduces instrument time and complexity compared with fractionation-based approaches, improving throughput for larger studies.

Future trends and potential applications

• Scale-up: Applying the workflow to larger, well-phenotyped cohorts and longitudinal samples to validate and refine candidate biomarker panels and to stratify OA endotypes.
• Targeted translation: Converting discovery signatures into targeted MS assays (PRM/MRM) or high-sensitivity immunoassays for clinical validation and eventual diagnostic use.
• Multi-omics integration: Combining SF proteomics with synovial transcriptomics, metabolomics and imaging to build comprehensive molecular phenotypes of OA and identify causal pathways.
• Technical advances: Further improvements in ion-mobility–enhanced acquisition and data-analysis algorithms may increase sensitivity for low-abundance species and streamline label-free quantification across large cohorts.
• Clinical deployment: Development of standardized pre-analytical protocols, quality controls and reference materials for SF will be important for reproducible, multi-center biomarker validation.

Conclusion

The study demonstrates that coupling PreOmics Enrich-iST sample preparation with the timsTOF Ultra AIP platform and dia-PASEF acquisition yields unprecedented depth of synovial fluid proteomes from minimal sample volumes, with excellent reproducibility. The approach discriminates OA from control samples and highlights biologically plausible changes—particularly in matrix metalloproteinases, extracellular matrix remodeling, inflammation and immune response—supporting its utility for OA biomarker discovery. Larger validation studies and targeted assay development are needed to translate these findings toward clinical applications.

References

1. Peffers MJ, Smagul A, Anderson JR. Expert Rev Proteomics. 2019;16(4):287–302.

COI: Two authors are employees of Bruker Scientific LLC and one is an employee of PreOmics; this was disclosed by the authors in the original report.